ARWR Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.30%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $9,210,434.97

Arrowhead Pharmaceuticals Insider Trading History Chart

Arrowhead Pharmaceuticals Share Price & Price History

^$64.66

▼ -0.41 (-0.63%)

As of 12/4/2025 05:00 PM ET

Days: 30 | 90 | 365

Arrowhead Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/28/2025	Mauro Ferrari	Director	Sell	8,750	$56.39	$493,412.50	68,764
10/1/2025	James C. Hamilton	Insider	Sell	20,000	$35.00	$700,000.00	212,122
9/12/2025	James C. Hamilton	Insider	Sell	15,000	$30.00	$450,000.00	232,122
9/2/2025	James C. Hamilton	Insider	Sell	15,000	$25.00	$375,000.00	247,122
8/15/2025	James C. Hamilton	Insider	Sell	9,389	$20.00	$187,780.00	262,122
8/13/2025	James C. Hamilton	Insider	Sell	611	$20.00	$12,220.00	271,511
4/11/2025	Christopher Richard Anzalone	CEO	Sell	50,800	$11.49	$583,692.00	3,921,255
4/9/2025	Christopher Richard Anzalone	CEO	Sell	40,322	$10.07	$406,042.54	4,022,055
3/13/2025	Christopher Richard Anzalone	CEO	Sell	51,425	$15.07	$774,974.75	4,062,377
3/4/2025	Christopher Richard Anzalone	CEO	Sell	133,333	$17.02	$2,269,327.66	3,773,802
1/23/2025	Adeoye Y. Olukotun	Director	Sell	959	$21.00	$20,139.00	35,781
1/6/2025	James C. Hamilton	Insider	Sell	32,729	$19.82	$648,688.78	272,122
1/6/2025	Kenneth Allen Myszkowski	CFO	Sell	27,167	$19.83	$538,721.61	473,433
1/6/2025	Patrick C. O'Brien	COO	Sell	29,184	$19.82	$578,426.88	535,201
1/2/2025	Christopher Richard Anzalone	CEO	Sell	11,520	$19.05	$219,456.00	3,764,252
12/27/2024	Adeoye Y. Olukotun	Director	Sell	2,850	$20.00	$57,000.00	36,740
12/23/2024	Christopher Richard Anzalone	CEO	Sell	12,563	$19.59	$246,109.17	3,775,772
12/18/2024	Christopher Richard Anzalone	CEO	Sell	26,712	$21.24	$567,362.88	3,688,335
12/16/2024	William D. Waddill	Director	Sell	3,748	$21.90	$82,081.20	44,125
7/2/2024	Tracie Oliver	Insider	Sell	9,394	$25.28	$237,480.32	127,107
5/2/2024	Victoria Vakiener	Director	Sell	1,799	$23.31	$41,934.69	30,205
3/20/2024	Hongbo Lu	Director	Buy	1,000	$27.50	$27,500.00	33,680
3/18/2024	Hongbo Lu	Director	Buy	1,000	$27.49	$27,490.00	31,680
3/6/2024	Kenneth Allen Myszkowski	CFO	Sell	40,000	$35.19	$1,407,600.00	400,600
1/31/2024	Christopher Richard Anzalone	CEO	Sell	57,499	$32.35	$1,860,092.65	3,715,048
1/12/2024	James C. Hamilton	Insider	Sell	7,940	$36.89	$292,906.60	210,851
1/11/2024	Douglas B Given	Director	Sell	2,911	$38.06	$110,792.66	129,711
1/5/2024	James C. Hamilton	Insider	Sell	32,143	$35.18	$1,130,790.74	218,791
1/5/2024	Kenneth Allen Myszkowski	CFO	Sell	16,104	$35.27	$567,988.08	440,600
1/5/2024	Patrick C. O'Brien	COO	Sell	22,841	$35.27	$805,602.07	464,385
1/3/2024	James C. Hamilton	Insider	Sell	6,300	$32.19	$202,797.00	175,934
1/3/2024	Patrick C. O'Brien	COO	Sell	8,749	$32.28	$282,417.72	403,826
1/2/2024	Christopher Richard Anzalone	CEO	Sell	9,952	$31.01	$308,611.52	3,715,048
12/20/2023	Christopher Richard Anzalone	CEO	Sell	12,000	$28.54	$342,480.00	3,725,000
11/20/2023	Javier San Martin	Insider	Sell	19,700	$28.80	$567,360.00	131,800
10/25/2023	Christopher Richard Anzalone	CEO	Sell	24,338	$24.21	$589,222.98	3,737,000
9/28/2023	Victoria Vakiener	Director	Sell	1,550	$26.33	$40,811.50	21,734
9/18/2023	Christopher Richard Anzalone	CEO	Sell	57,755	$28.12	$1,624,070.60	3,761,338
7/3/2023	Tracie Oliver	Insider	Sell	8,925	$35.31	$315,141.75	61,575
6/30/2023	James C. Hamilton	Insider	Sell	3,000	$35.53	$106,590.00	188,484
6/27/2023	Kenneth Allen Myszkowski	CFO	Sell	15,000	$36.20	$543,000.00	381,704
5/5/2023	Douglas B Given	Director	Sell	6,500	$40.90	$265,850.00	117,635
5/3/2023	Christopher Richard Anzalone	CEO	Sell	54,928	$39.14	$2,149,881.92	3,761,338
3/3/2023	Adeoye Y. Olukotun	Director	Sell	11,350	$32.65	$370,577.50	7,867
2/27/2023	Douglas B Given	Director	Sell	875	$32.62	$28,542.50	13,000
1/9/2023	William D. Waddill	Director	Sell	3,200	$30.00	$96,000.00	28,950
1/5/2023	James C. Hamilton	Insider	Sell	13,803	$37.40	$516,232.20	191,484
1/5/2023	Patrick C. O'Brien	COO	Sell	15,000	$37.39	$560,850.00	413,375
1/3/2023	James C. Hamilton	Insider	Sell	10,338	$38.38	$396,772.44	145,287
1/3/2023	Patrick C. O'Brien	COO	Sell	17,500	$38.33	$670,775.00	363,375
12/29/2022	Kenneth Allen Myszkowski	CFO	Sell	30,625	$40.00	$1,225,000.00	336,704

SEC Filings (Institutional Ownership Changes) for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

62.61% of Arrowhead Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Arrowhead Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
12/2/2025	IFP Advisors Inc	14,593	$0.54M	0.0%	-1.8%	0.011%
12/1/2025	Cantor Fitzgerald L. P.	19,500	$0.67M	0.0%	+14.7%	0.014%
11/21/2025	CIBC Bancorp USA Inc.	12,860	$0.44M	0.0%	N/A	0.009%
11/17/2025	Keystone Financial Group	8,000	$0.28M	0.0%	N/A	0.006%
11/17/2025	CANADA LIFE ASSURANCE Co	129,958	$4.39M	0.0%	+11.7%	0.094%
11/17/2025	Woodline Partners LP	1,000,158	$34.50M	0.2%	+34.0%	0.723%
11/17/2025	PDT Partners LLC	90,819	$3.13M	0.2%	-40.6%	0.066%
11/17/2025	Virtus Advisers LLC	14,462	$0.50M	0.3%	+581.5%	0.010%
11/17/2025	Voloridge Investment Management LLC	402,659	$13.89M	0.0%	N/A	0.291%
11/17/2025	Velan Capital Investment Management LP	6,500	$0.22M	0.2%	N/A	0.005%
11/17/2025	Verition Fund Management LLC	33,203	$1.15M	0.0%	+42.3%	0.024%
11/17/2025	Prelude Capital Management LLC	28,658	$0.99M	0.1%	N/A	0.021%
11/17/2025	Nomura Holdings Inc.	39,218	$1.35M	0.0%	-390.2%	0.028%
11/17/2025	Millennium Management LLC	109,807	$3.79M	0.0%	-35.0%	0.079%
11/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	138,020	$4.76M	0.0%	-8.8%	0.100%
11/17/2025	Integrated Wealth Concepts LLC	6,577	$0.23M	0.0%	N/A	0.005%
11/17/2025	Jain Global LLC	53,957	$1.86M	0.0%	N/A	0.039%
11/17/2025	Gotham Asset Management LLC	31,863	$1.10M	0.0%	+68.9%	0.023%
11/17/2025	Fred Alger Management LLC	306,833	$10.58M	0.0%	N/A	0.222%
11/17/2025	Focus Partners Wealth	22,110	$0.76M	0.0%	+24.2%	0.016%
11/17/2025	Baker BROS. Advisors LP	1,670,762	$57.63M	0.4%	+77.9%	1.208%
11/17/2025	Cantor Fitzgerald L. P.	19,500	$0.67M	0.0%	+14.7%	0.014%
11/17/2025	Bank of America Corp DE	760,687	$26.24M	0.0%	+21.5%	0.550%
11/17/2025	Boothbay Fund Management LLC	83,388	$2.88M	0.0%	+34.6%	0.060%
11/17/2025	Aquatic Capital Management LLC	25,671	$0.89M	0.0%	-72.7%	0.019%
11/17/2025	Algert Global LLC	81,310	$2.80M	0.0%	-20.7%	0.059%
11/17/2025	Alliancebernstein L.P.	155,894	$5.38M	0.0%	-2.0%	0.113%
11/17/2025	Ameriprise Financial Inc.	274,163	$9.46M	0.0%	+2.7%	0.198%
11/14/2025	Schonfeld Strategic Advisors LLC	543,916	$18.76M	0.1%	+12.8%	0.393%
11/14/2025	Creative Planning	52,006	$1.79M	0.0%	+13.9%	0.038%
11/14/2025	Raymond James Financial Inc.	227,269	$7.84M	0.0%	+33.9%	0.164%
11/14/2025	Amundi	28,156	$1.06M	0.0%	+11.8%	0.020%
11/14/2025	Deerfield Management Company L.P.	993,000	$34.25M	0.5%	N/A	0.718%
11/14/2025	ADAR1 Capital Management LLC	49,800	$1.72M	0.2%	-9.8%	0.036%
11/14/2025	Zurcher Kantonalbank Zurich Cantonalbank	36,775	$1.27M	0.0%	+9.7%	0.027%
11/14/2025	Balyasny Asset Management L.P.	792,966	$27.35M	0.0%	N/A	0.574%
11/14/2025	Longaeva Partners L.P.	125,673	$4.33M	0.6%	N/A	0.091%
11/14/2025	UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC	1,759,489	$60.69M	0.0%	-34.5%	1.273%
11/14/2025	Integral Health Asset Management LLC	225,000	$7.76M	0.5%	N/A	0.163%
11/14/2025	Avoro Capital Advisors LLC	10,900,000	$375.94M	4.9%	+2.8%	7.884%
11/14/2025	iSAM Funds UK Ltd	834	$29K	0.0%	N/A	0.001%
11/14/2025	Comerica Bank	38,960	$1.34M	0.0%	-10.3%	0.028%
11/13/2025	Marshall Wace LLP	1,436,840	$49.56M	0.1%	-33.4%	1.039%
11/13/2025	Entropy Technologies LP	10,473	$0.36M	0.0%	N/A	0.008%
11/13/2025	Invesco Ltd.	502,892	$17.35M	0.0%	-34.1%	0.364%
11/13/2025	Arrowstreet Capital Limited Partnership	2,081,689	$71.80M	0.0%	+3,142.5%	1.506%
11/13/2025	UBS Group AG	918,183	$31.67M	0.0%	-42.6%	0.664%
11/13/2025	Capital Fund Management S.A.	35,140	$1.21M	0.0%	-86.2%	0.025%
11/13/2025	BNP Paribas Financial Markets	50,964	$1.76M	0.0%	+50.7%	0.037%
11/13/2025	Mackenzie Financial Corp	10,176	$0.35M	0.0%	N/A	0.007%
11/13/2025	Franklin Resources Inc.	116,504	$4.02M	0.0%	+43.4%	0.084%
11/13/2025	Quadrant Capital Group LLC	4,067	$0.14M	0.0%	N/A	0.003%
11/13/2025	Legal & General Group Plc	386,374	$13.33M	0.0%	-5.1%	0.279%
11/13/2025	Swiss National Bank	214,100	$7.38M	0.0%	+2.0%	0.155%
11/13/2025	WINTON GROUP Ltd	28,945	$1M	0.0%	-30.7%	0.021%
11/13/2025	Russell Investments Group Ltd.	12,884	$0.44M	0.0%	+377.9%	0.009%
11/13/2025	Private Advisor Group LLC	10,763	$0.37M	0.0%	-4.4%	0.008%
11/13/2025	Pinnacle Associates Ltd.	203,314	$7.01M	0.1%	-3.9%	0.147%
11/13/2025	Natixis Advisors LLC	55,644	$1.92M	0.0%	N/A	0.040%
11/13/2025	First Trust Advisors LP	207,955	$7.17M	0.0%	N/A	0.150%
11/12/2025	Barclays PLC	350,239	$12.08M	0.0%	-14.5%	0.253%
11/12/2025	Crossmark Global Holdings Inc.	7,340	$0.25M	0.0%	N/A	0.005%
11/12/2025	Dimensional Fund Advisors LP	474,462	$16.36M	0.0%	+29.4%	0.343%
11/12/2025	Cresset Asset Management LLC	14,552	$0.50M	0.0%	N/A	0.011%
11/12/2025	Victory Capital Management Inc.	45,169	$1.56M	0.0%	-5.3%	0.033%
11/12/2025	Fisher Asset Management LLC	1,053,794	$36.35M	0.0%	+133.3%	0.762%
11/12/2025	London & Capital Asset Management Ltd	10,700	$0.37M	0.0%	N/A	0.008%
11/12/2025	Rafferty Asset Management LLC	114,379	$3.95M	0.0%	-19.4%	0.083%
11/12/2025	Quantbot Technologies LP	11,197	$0.39M	0.0%	N/A	0.008%
11/12/2025	Erste Asset Management GmbH	73,000	$2.47M	0.0%	+55.3%	0.053%
11/12/2025	Xponance Inc.	9,499	$0.33M	0.0%	N/A	0.007%
11/12/2025	IvyRock Asset Management HK Ltd	10,500	$0.36M	0.2%	N/A	0.008%
11/12/2025	Intech Investment Management LLC	36,382	$1.26M	0.0%	-39.9%	0.026%
11/10/2025	Ameritas Investment Partners Inc.	10,079	$0.35M	0.0%	-19.3%	0.007%
11/10/2025	Koshinski Asset Management Inc.	6,749	$0.23M	0.0%	N/A	0.005%
11/10/2025	Citigroup Inc.	51,582	$1.78M	0.0%	-63.4%	0.037%
11/10/2025	China Universal Asset Management Co. Ltd.	42,234	$1.46M	0.1%	+52.3%	0.031%
11/7/2025	King Luther Capital Management Corp	80,640	$2.78M	0.0%	+54.7%	0.058%
11/7/2025	NEOS Investment Management LLC	31,795	$1.10M	0.0%	-10.1%	0.023%
11/7/2025	Vanguard Group Inc.	16,035,870	$553.08M	0.0%	+3.3%	11.599%
11/7/2025	JPMorgan Chase & Co.	775,717	$26.75M	0.0%	+90.3%	0.561%
11/7/2025	PNC Financial Services Group Inc.	10,924	$0.38M	0.0%	+3.1%	0.008%
11/7/2025	HighTower Advisors LLC	132,889	$4.58M	0.0%	+7.2%	0.096%
11/7/2025	Aberdeen Group plc	520,644	$17.96M	0.0%	-45.8%	0.377%
11/6/2025	Public Sector Pension Investment Board	539,336	$18.60M	0.1%	+25.9%	0.390%
11/6/2025	Rhumbline Advisers	371,112	$12.80M	0.0%	+3.1%	0.268%
11/6/2025	Johnson Investment Counsel Inc.	22,635	$0.78M	0.0%	N/A	0.016%
11/6/2025	Profund Advisors LLC	29,434	$1.02M	0.0%	-13.1%	0.021%
11/6/2025	ProShare Advisors LLC	27,958	$0.96M	0.0%	-13.1%	0.020%
11/5/2025	Smartleaf Asset Management LLC	1,692	$57K	0.0%	+2,186.5%	0.001%
11/5/2025	Alps Advisors Inc.	65,204	$2.25M	0.0%	-12.5%	0.047%
11/5/2025	Envestnet Asset Management Inc.	14,828	$0.51M	0.0%	N/A	0.011%
11/4/2025	Allianz Asset Management GmbH	10,300	$0.36M	0.0%	N/A	0.007%
11/4/2025	State of Wyoming	9,519	$0.33M	0.0%	+5.6%	0.007%
11/4/2025	Principal Financial Group Inc.	780,132	$26.91M	0.0%	+25.2%	0.564%
11/4/2025	Thrivent Financial for Lutherans	99,744	$3.44M	0.0%	+7.9%	0.072%
11/4/2025	Privium Fund Management B.V.	473,951	$16.35M	2.9%	-22.6%	0.343%
11/3/2025	AlphaQuest LLC	2,080	$72K	0.0%	-93.6%	0.002%
11/3/2025	Arizona State Retirement System	32,661	$1.13M	0.0%	+1.9%	0.024%
11/3/2025	Summit Global Investments	9,934	$0.34M	0.0%	N/A	0.007%

Data available starting January 2016

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Today's Range

Now: $64.66

$64.19

$67.14

50 Day Range

MA: $41.44

$32.80

$65.07

52 Week Range

Now: $64.66

$9.57

$67.14

Volume

3,059,404 shs

Average Volume

2,655,865 shs

Market Capitalization

$8.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28

Who are the company insiders with the largest holdings of Arrowhead Pharmaceuticals?: Arrowhead Pharmaceuticals' top insider shareholders include:
Christopher Richard Anzalone (CEO)
Patrick O'brien (COO)
Kenneth Allen Myszkowski (CFO)
James C Hamilton (Insider)
Douglas B Given (Director)
Tracie Oliver (Insider)
Mauro Ferrari (Director)
William D Waddill (Director)
Adeoye Y Olukotun (Director)
Hongbo Lu (Director)
Victoria Vakiener (Director)
Learn More about top insider investors at Arrowhead Pharmaceuticals.
Who are the major institutional investors of Arrowhead Pharmaceuticals?: Arrowhead Pharmaceuticals' top institutional shareholders include:
Vanguard Group Inc. — 11.60%
Avoro Capital Advisors LLC — 7.88%
Arrowstreet Capital Limited Partnership — 1.51%
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC — 1.27%
Baker BROS. Advisors LP — 1.21%
Marshall Wace LLP — 1.04%
Learn More about top institutional investors of Arrowhead Pharmaceuticals stock.
Which institutional investors are selling Arrowhead Pharmaceuticals stock?: During the last quarter, ARWR stock was sold by these institutional investors:
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC
Marshall Wace LLP
UBS Group AG
Aberdeen Group plc
Invesco Ltd.
Capital Fund Management S.A.
Privium Fund Management B.V.
Citadel Advisors LLC
In the last year, company insiders that have sold Arrowhead Pharmaceuticals company stock include:
Christopher Richard Anzalone (CEO)
Patrick O'brien (COO)
Kenneth Allen Myszkowski (CFO)
James C Hamilton (Insider)
Douglas B Given (Director)
Tracie Oliver (Insider)
Mauro Ferrari (Director)
Learn More investors selling Arrowhead Pharmaceuticals stock.
Which institutional investors are buying Arrowhead Pharmaceuticals stock?: Within the last quarter, ARWR stock was acquired by institutional investors including:
Arrowstreet Capital Limited Partnership
Deerfield Management Company L.P.
Balyasny Asset Management L.P.
Baker BROS. Advisors LP
Fisher Asset Management LLC
Vanguard Group Inc.
Voloridge Investment Management LLC
JPMorgan Chase & Co.